Aimovig (erenumab-aooe) / Amgen, Novartis 
Welcome,         Profile    Billing    Logout  
 12 Diseases   17 Trials   17 Trials   2487 News 


«12345678910111213...2425»
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal, HEOR, Real-world evidence, Real-world:  Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study. (Pubmed Central) -  Aug 13, 2023   
    Higher photophobia ratios were associated with higher response rates between three and six months. It could indicate an involvement of peripheral CGRP in photophobia as well as a central modulation of migraine through these treatments which mainly act on the periphery.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Pan-Colitis Secondary to Calcitonin Gene-Related Peptide (CGRP) Antagonist for Migraines (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_3591;    
    The patient was started on IV methylprednisolone BID, along with dicyclomine...She continued to improve after 3 days of IV steroids and was discharged with tapered prednisone...In terms of the pathophysiology, this suggests that Erenumab may not only cause direct cytotoxicity via mucosal damage, but it may also contribute to colonic ischemia. Figure: Figure A and B: Patient
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Aimovig (erenumab-aooe) / Amgen, Novartis
    What (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_1836;    
    These two cases of CGRP antagonist induced gastroparesis highlight important side effects to consider when deciding on a treatment plan for patients with migraines as well as a differential diagnosis to include for patients with gastroparesis. Figure: Figure 1 - Food residue noted on EGD Figure 2A - Nuclear medicine GES results with anterior and posterior views showing moderate retention of food in the stomach after 4 hours indicative of grade 2 gastroparesis Figure 2B - Graphic representation of GES results showing 50% gastric emptying time of 148 minutes and 21% retention at 4 hours
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Enrollment closed:  CHERUB01: Efficacy of Erenumab in Chronic Cluster Headache (clinicaltrials.gov) -  Jul 27, 2023   
    P2,  N=101, Active, not recruiting, 
    Figure: Figure 1 - Food residue noted on EGD Figure 2A - Nuclear medicine GES results with anterior and posterior views showing moderate retention of food in the stomach after 4 hours indicative of grade 2 gastroparesis Figure 2B - Graphic representation of GES results showing 50% gastric emptying time of 148 minutes and 21% retention at 4 hours Recruiting --> Active, not recruiting
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal:  Harlequin syndrome. (Pubmed Central) -  Jul 17, 2023   
    He was started on erenumab for migraine prophylaxis and was given sumatriptan for abortive therapy following which his headaches improved. The patient was diagnosed with idiopathic left Horner's syndrome and his migraines with autonomic dysfunction would present with unilateral flushing opposite to the site of Horner's presenting as Harlequin syndrome [1, 2].
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial primary completion date:  Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder (clinicaltrials.gov) -  Jul 12, 2023   
    P2,  N=30, Recruiting, 
    The patient was diagnosed with idiopathic left Horner's syndrome and his migraines with autonomic dysfunction would present with unilateral flushing opposite to the site of Horner's presenting as Harlequin syndrome [1, 2]. Trial primary completion date: Sep 2023 --> Dec 2023
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal:  Revisiting dose-finding of monoclonal antibodies in migraine. (Pubmed Central) -  Jun 14, 2023   
    We present a clinical case, i.e. a female migraine patient who mistakenly administered supratherapeutic (three-fold higher) doses of erenumab leading to more efficacious clinical responses without any side-effects...Indeed, the dose-finding studies were mainly performed in relatively young and normal-weight males, while most phase III/IV trials are marked by a high female-to-male ratio, mainly consisting of overweight to obese females. Considering these aspects in future trials could optimize healthcare for a larger proportion of migraine patients.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
    Retrospective data, Journal:  Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 (Pubmed Central) -  Jun 7, 2023   
    Further studies are needed to confirm these findings. Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65
  • ||||||||||  Journal:  Drugs for migraine. (Pubmed Central) -  Jun 6, 2023   
    No abstract available No abstract available
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal:  Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study. (Pubmed Central) -  Jun 5, 2023   
    Overall, monthly fremanezumab 225 The effectiveness of anti-CGRP monoclonal antibodies is almost the same between women in menopause and women of childbearing age, without appreciable differences between the different antibodies.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial primary completion date:  EMBRACE: Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine (clinicaltrials.gov) -  Jun 1, 2023   
    P4,  N=576, Recruiting, 
    The effectiveness of anti-CGRP monoclonal antibodies is almost the same between women in menopause and women of childbearing age, without appreciable differences between the different antibodies. Trial completion date: Jul 2024 --> Nov 2023 | Trial primary completion date: Jul 2024 --> Nov 2023
  • ||||||||||  Journal:  Migraine Medication (Pubmed Central) -  May 21, 2023   
    Monoclonal antibodies targeting CGRP (galcanezumab and fremanezumab) and its receptor (erenumab) have shown consistent efficacy in migraine prophylaxis, with excellent safety profiles. Its effects on refractory cases have also been reported, and a paradigm shift in migraine treatment is emerging.
  • ||||||||||  Review, Journal:  Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. (Pubmed Central) -  May 15, 2023   
    The present narrative review aim to provide a critical appraisal of phase II and III CGRP-mAbs and gepants trials to analyse their use in clinical practice. Despite monoclonal antibodies against CGRP pathway and gepants can be undoubtedly considered top-of-the-range treatments, there are still issues deserving to be addressed in the coming years as the risk of off-target effects as well as their economic sustainability based on the considerable migraine burden.
  • ||||||||||  Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
    Trial termination, HEOR, Real-world evidence, Real-world effectiveness, Real-world:  EVEC: Real World Effectiveness of Eptinezumab in Participants With Migraine (clinicaltrials.gov) -  May 11, 2023   
    P4,  N=32, Terminated, 
    Despite monoclonal antibodies against CGRP pathway and gepants can be undoubtedly considered top-of-the-range treatments, there are still issues deserving to be addressed in the coming years as the risk of off-target effects as well as their economic sustainability based on the considerable migraine burden. Completed --> Terminated; The study was terminated due to enrolment challenges.
  • ||||||||||  Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial primary completion date:  Effectiveness of a Health Education Programme for Prevention of Chronic Migraine: A Randomized Clinical Trial (clinicaltrials.gov) -  May 11, 2023   
    P=N/A,  N=182, Recruiting, 
    Completed --> Terminated; The study was terminated due to enrolment challenges. Trial completion date: Apr 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Oct 2023
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Erenumab for Idiosyncratic Facial Pain (clinicaltrials.gov) -  May 9, 2023   
    P4,  N=29, Active, not recruiting, 
    This suggests that patients with initial benefit on lower dose erenumab should be monitored for change to effectiveness. Recruiting --> Active, not recruiting | N=66 --> 29 | Trial completion date: Feb 2024 --> Aug 2023 | Trial primary completion date: Jan 2024 --> Aug 2023
  • ||||||||||  Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
    Trial completion, HEOR, Real-world evidence, Real-world effectiveness, Real-world:  EVEC: Real World Effectiveness of Eptinezumab in Participants With Migraine (clinicaltrials.gov) -  May 1, 2023   
    P4,  N=32, Completed, 
    However, within these categories, specific criteria from different MCOs varied significantly. Active, not recruiting --> Completed
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Review, Journal:  Erenumab efficacy in migraine headache prophylaxis: A systematic review. (Pubmed Central) -  Apr 4, 2023   
    However, since the design has multiple limitations, further prospective studies are required to validate these data. Erenumab had remarkable efficacy in the short and long-term treatment of episodic and chronic migraine, notably the patients with difficult-to-treat migraine headaches.